moatshark My

All holdings

Core Scientific

CORZ

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$128m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$25.59
+71.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-18.8%Q4 ’25
+2.7%Q1 ’26
+71.1%Q2 ’26
Q4 ’25: -18.8%; Q1 ’26: +2.7%; Q2 ’26: +71.1%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Core Scientific.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Core Scientific
Oaktree Capital Management1.8%$128m$128mTrimmed -47%4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Core Scientific
Bought or soldFiling
19 Oct 2026Duchene Todd MSee remarks▼ Sold10,000$13.87$139kForm 4
12 Oct 2026Duchene Todd MSee remarks▼ Sold10,000$15.12$151kForm 4
5 Oct 2026Duchene Todd MSee remarks▼ Sold10,000$16.31$163kForm 4
28 Sep 2026Duchene Todd MSee remarks▼ Sold10,000$16.76$168kForm 4
21 Sep 2026Duchene Todd MSee remarks▼ Sold10,000$18.37$184kForm 4
15 Sep 2026Weiss Eric StantonDirector▲ Bought6,000$16.33$98kForm 4
14 Sep 2026Duchene Todd MSee remarks▼ Sold10,000$17.14$171kForm 4
8 Sep 2026Duchene Todd MSee remarks▼ Sold10,000$18.67$187kForm 4
31 Aug 2026Duchene Todd MSee remarks▼ Sold10,000$16.23$162kForm 4
24 Aug 2026Duchene Todd MSee remarks▼ Sold10,000$17.45$174kForm 4
20 Aug 2026Crain ElizabethDirector▲ Bought6,000$18.33$110kForm 4
18 Aug 2026Weiss Eric StantonDirector▲ Bought7,000$19.19$134kForm 4
17 Aug 2026Duchene Todd MSee remarks▼ Sold10,000$20.10$201kForm 4
10 Aug 2026Duchene Todd MSee remarks▼ Sold9,000$19.90$179kForm 4
10 Aug 2026Duchene Todd MSee remarks▼ Sold1,000$20.65$21kForm 4
3 Aug 2026Duchene Todd MSee remarks▼ Sold7,500$22.62$170kForm 4
3 Aug 2026Duchene Todd MSee remarks▼ Sold1,500$21.55$32kForm 4
3 Aug 2026Duchene Todd MSee remarks▼ Sold1,000$20.39$20kForm 4
27 Jul 2026Duchene Todd MSee remarks▼ Sold8,300$20.75$172kForm 4
27 Jul 2026Duchene Todd MSee remarks▼ Sold1,600$21.89$35kForm 4

About the company

Sector
Financials · Finance Services
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
321m at 23 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$60.3m2020
$544m2021
$640m2022
$502m2023
$511m2024
$319m2025
2020: $60.3m; 2021: $544m; 2022: $640m; 2023: $502m; 2024: $511m; 2025: $319m
Core Scientific revenue and net income by year
YearRevenueNet income
2025$319m−$289m
2024$511m−$1.4bn
2023$502m−$246m
2022$640m−$2.1bn
2021$544m$47.3m
2020$60.3m−$12.2m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.